• First results from InhaTarget Therapeutics study on Sofra platform
• Novel lung delivery method shows Sofra's versatility
• Data confirms anti-inflammatory properties of Sofra drug in lung

Noxopharm Limited (ASX:NOX) has announced first study results from a collaboration with InhaTarget Therapeutics, a Belgian company developing innovative treatments for lung-related diseases via a unique inhalation-based delivery system. The companies have been working together since 2024 to test Noxopharm's Sofra technology platform assets within the context of lung inflammation. InhaTarget has successfully developed an optimized formulation process and evaluated the payload potential of Sofra oligonucleotides. The studies showed successful encapsulation of Noxopharm's TLR7/8-inhibiting oligonucleotides in InhaTarget's proprietary lipid nanoparticles (LNPs), resulting in a significant reduction of over 75% in lung inflammation in an animal model. This delivery method marks a new addition to the ways in which Noxopharm's oligonucleotides can be delivered to target tissues. The collaboration showcases the versatility of the Sofra platform and its potential applications in lung-related diseases, which represent a significant and growing global health burden. Noxopharm and InhaTarget plan to expand their collaboration in the coming months with the aim of advancing this technology toward clinical trials.

Noxopharm did not provide any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in the announcement.

Noxopharm and InhaTarget plan to expand their collaboration in the coming months and aim to advance the Sofra lung delivery technology toward clinical trials.